Table 2.
Induction and Maintenance Infliximab Levels Associated With UC Outcomes
| Study | Time Point, wk | Target IFX Level, μg/mL | Outcome | Sensitivity/Specificity, % |
|---|---|---|---|---|
| Kobayashi et al.101 | 2 | >21.3 | Clinical remission (wk14) | 61/69 |
| Papamichael et al.102 | 2 | <16.5 | Colectomy | 80/70 |
| Papamichael et al.71 | 2 | ≥28.3 | Mucosal healing (wk10–14) | NR |
| Adedokun et al.73 | 6 | >22 | Clinical response (wk8) | 60/62 |
| Papamichael et al.71 | 6 | ≥15 | Mucosal healing (wk10–14) | 60/74 |
| Brandse et al.70 | 6 | >6.6 | Endoscopic response (wk8) | 88/73 |
| Adedokun et al.73 | 8 | >41.2 | Clinical response (wk8) | 63/62 |
| Adedokun et al.74 | 8 | >41.1 | Mucosal healing | NR |
| Papamichael et al.71 | 14 | ≥2.1 | Mucosal healing (wk10–14) | 84/62 |
| Adedokun et al.73 | 14 | >5.1 | Clinical response (wk30) | 66/63 |
| Adedokun et al.73 | 14 | >3.5 | Clinical response (wk54) | 82/50 |
| Arias et al.103 | 14 | >2.5 | Relapse-free survival (mo6) | 81/75 |
| Van Stappen et al.104 | 14 | ≥2.1 | Mucosal healing (wk10–14) | 100/50 |
| Adedokun et al.73 | 30 | >3.7 | Clinical response (wk30) | 65/71 |
Abbreviations: ATI, antibodies to infliximab; IFX, infliximab; NR, not reported.